At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
VRC-HIVADV014-00-VPbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade, Multivalent Recombinant Adenoviral Vector HIV Vaccine, VRC-HIVADV014-00-VP, in Healthy, HIV-1 Uninfected Adult Participants Who Have Low Titers of Pre-Existing Ad5 Neutralizing Antibodies
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jul 14, 2005·Updated Oct 14, 2021
In Brief
A Phase 1 clinical trial evaluating VRC-HIVADV014-00-VP for HIV Infections. Completed, enrolled 48 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine the safety of and immune response to an experimental HIV vaccine in HIV uninfected individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2005
Study CompletionOct 2006
TodayJul 2026
First PostedJul 14, 2005
Study CompletionOct 1, 2006
TodayJul 2, 2026
Posted 21.0 years ago
Interventions
VRC-HIVADV014-00-VPbiological